Tevogen Bio (NASDAQ:TVGN) Issues Earnings Results, Beats Estimates By $1.01 EPS

Tevogen Bio (NASDAQ:TVGN) issued its quarterly earnings results on Thursday. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.53) by $1.01, FiscalAI reports.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN traded up $0.30 during trading on Friday, hitting $6.87. 8,215 shares of the company were exchanged, compared to its average volume of 12,930. The firm’s 50 day moving average price is $6.94 and its 200-day moving average price is $8.33. Tevogen Bio has a 12-month low of $3.64 and a 12-month high of $49.50. The stock has a market capitalization of $28.98 million, a P/E ratio of -1.49 and a beta of 0.18.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research report on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $100.00.

Hedge Funds Weigh In On Tevogen Bio

Several hedge funds have recently made changes to their positions in TVGN. Bridgeway Capital Management LLC increased its position in shares of Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after purchasing an additional 33,000 shares in the last quarter. Deutsche Bank AG increased its position in Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.